Zentalis Pharma (NASDAQ:ZNTL) just reported results for the first quarter of 2024.
- Zentalis Pharma reported earnings per share of 14 cents. This was above the analyst estimate for EPS of -77 cents.
- The company reported revenue of $40.56 million.
- This was 209.15% better than the analyst estimate for revenue of $13.12 million.